Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice: a randomised real-life study Source: Eur Respir J 2006; 28: Suppl. 50, 613s Year: 2006
Budesonide/formoterol adjustable maintenance dosing and fixed dosing in adolescents with asthma: a Swedish study Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003
Adjustable maintenance dosing with budesonide/formoterol controls asthma symptom severity and maintains lung function with a lower overall dose than fixed dosing: results of an Italian study Source: Eur Respir J 2003; 22: Suppl. 45, 259s Year: 2003
Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – a 5-month study in Canada Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003
Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than with fixed dosing – 6-month study Source: International Congress 2018 – Asthma and drugs Year: 2018
Long-term efficacy of a home-based airway clearance programme to improve cough severity in patients with bronchiectasis:a randomised controlled trial> Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections Year: 2019
Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – 3-month study Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017
Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double-blind study Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007
Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than fixed dosing: results of a study in Italy Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003
Adjustable maintenance treatment with budesonide/formoterol combination rapidly improves and maintains quality of life in asthma patients Source: Eur Respir J 2002; 20: Suppl. 38, 41s Year: 2002
Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015
Adjustable dosing with budesonide/formoterol achieves sustained guideline ‘well-controlled asthma‘ following step down in treatment Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Total costs according to reliever use of formoterol turbuhaler in asthma: results from the RELIEF worldwide randomized effectiveness study, stratified by maintenance medication levels Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002
QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial. Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017
A double-blind, double-dummy, randomized study of beclomethasone/formoterol versus fluticasone/salmeterol in treatment of moderate to severe asthma in Taiwan Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
A randomised controlled trial to investigate the optimal dose and effect of salbutamol for the treatment of acute exacerbations of COPD Source: Eur Respir J 2002; 20: Suppl. 38, 244s Year: 2002